XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash Flows From Operating Activities:    
Net loss $ (22,581) $ (8,916)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 10,845 9,787
Amortization of debt discount 1,286 496
Unrealized loss on investments in equity securities 8,556 156
Realized loss on available-for-sale investments 80 85
Stock-based compensation expense 9,383 7,015
Loss on disposal of property and equipment 304 113
Provision for bad debt 35 215
Excess and obsolete inventory 546  
Insurance proceeds for operations 6,311  
Changes in operating assets and liabilities:    
Accounts receivable (4,291) (5,590)
Inventories (9,476) (1,138)
Prepaid expenses and other current assets (1,043) (512)
Deposits 27 230
Change in operating lease right-of-use assets and lease liabilities 27 220
Accounts payable and other accrued expenses (4,283) (4,983)
Accrued compensation and related expenses (1,581) (661)
Deferred revenue (151) 14
Deferred tax (asset) liability (481) 105
Net cash used in operating activities (6,487) (3,364)
Cash Flows From Investing Activities:    
Purchases of property and equipment (9,060) (6,705)
Insurance proceeds for loss of fixed assets 3,000  
Software development costs (564) (449)
Purchases of short-term investments (136,611) (241,993)
Sales/maturities of short-term investments 84,760 8,000
Acquisition of Cell&Co (2,107)  
Acquisition of CTSA and F-airGate   (5,019)
Patent and trademark costs (358) (109)
Net cash used in investing activities (60,940) (246,275)
Cash Flows From Financing Activities:    
Proceeds from exercise of stock options 597 3,483
Repurchase of common stock (33,349)  
Repayment of note payable (639)  
Repayment of capital lease obligation (18)  
Proceeds from public offering, net of $17.7 million in offering costs   269,825
Repayment of finance lease liabilities   (32)
Net cash (used in) provided by financing activities (33,409) 273,276
Effect of exchange rates on cash and cash equivalents (1,231) (153)
Net change in cash and cash equivalents (102,067) 23,484
Cash and cash equivalents - beginning of period 139,101 36,873
Cash and cash equivalents - end of period 37,034 60,357
Supplemental Disclosure of Non-Cash Financing Activities:    
Conversion of Series C Preferred Stock to common stock   765
Cost of Series C Preferred stock conversion included in additional paid-in-capital and accounts payable and accrued liabilities   1,800
CRYOPDP goodwill adjustment included in deferred tax liability   877
CRYOPDP goodwill adjustment included in fixed assets   71
MVE estimated working capital adjustment included in goodwill and accounts payable   500
Note valuation adjustment included in note payable and goodwill   275
Net unrealized loss on available-for-sale securities (19,374) (1,178)
Reclassification of realized loss on available-for-sale debt securities to earnings (46) (38)
Paid-in-kind preferred stock dividend 4,000 4,196
Fixed assets included in accounts payable and accrued liabilities 397 $ 3,868
Common stock issued for Cell&Co acquisition $ 479